PER2 and leukemia: Taken together, these data suggest an important cancer participation of an altered expression of miR-650 through 22q11.2 alterations by targeting different TSG, such as PER2 in leukemias and lymphomas, THBD in thyroid cancer, and both of them plus STAT5 in BRCA.